

Distinct Requirements for Cranial Ectoderm and Mesenchyme-Derived Wnts in Specification and Differentiation of Osteoblast and Dermal Progenitors

L. Henry Goodnough¹, Gregg J. DiNuoscio², James W. Ferguson², Trevor Williams³, Richard A. Lang⁴, Radhika P. Atit^{2,5,6*}

1 Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America, **2** Department of Biology, Case Western Reserve University, Cleveland, Ohio, United States of America, **3** Department of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado, United States of America, **4** Visual Systems Group, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America, **5** Department of Genetics, Case Western Reserve University, Cleveland, Ohio, United States of America, **6** Department of Dermatology Case Western Reserve University, Cleveland, Ohio, United States of America

Abstract

The cranial bones and dermis differentiate from mesenchyme beneath the surface ectoderm. Fate selection in cranial mesenchyme requires the canonical Wnt effector molecule β -catenin, but the relative contribution of Wnt ligand sources in this process remains unknown. Here we show Wnt ligands are expressed in cranial surface ectoderm and underlying supraorbital mesenchyme during dermal and osteoblast fate selection. Using conditional genetics, we eliminate secretion of all Wnt ligands from cranial surface ectoderm or undifferentiated mesenchyme, to uncover distinct roles for ectoderm- and mesenchyme-derived Wnts. Ectoderm Wnt ligands induce osteoblast and dermal fibroblast progenitor specification while initiating expression of a subset of mesenchymal Wnts. Mesenchyme Wnt ligands are subsequently essential during differentiation of dermal and osteoblast progenitors. Finally, ectoderm-derived Wnt ligands provide an inductive cue to the cranial mesenchyme for the fate selection of dermal fibroblast and osteoblast lineages. Thus two sources of Wnt ligands perform distinct functions during osteoblast and dermal fibroblast formation.

Citation: Goodnough LH, DiNuoscio GJ, Ferguson JW, Williams T, Lang RA, et al. (2014) Distinct Requirements for Cranial Ectoderm and Mesenchyme-Derived Wnts in Specification and Differentiation of Osteoblast and Dermal Progenitors. *PLoS Genet* 10(2): e1004152. doi:10.1371/journal.pgen.1004152

Editor: Gregory S. Barsh, Stanford University School of Medicine, United States of America

Received: February 7, 2013; **Accepted:** December 16, 2013; **Published:** February 20, 2014

Copyright: © 2014 Goodnough et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by Case Startup funds from Case Western Reserve University (RPA), National Institutes of Dental and Craniofacial Research [grants F31 DE020220-02 to LHG, R01 DE019843 to TW, and R01-DE01870 to RPA], and by the National Eye Institute (R01-EY016241 to RAL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: rpa5@case.edu

Introduction

The bones of the skull vault develop in close contact with the embryonic skin to enclose the brain. In the mouse embryo, both bone-forming osteoblasts and skin-forming dermal fibroblasts are derived from cranial neural crest and paraxial mesoderm [1]. At E11.5, cranial dermal fibroblast progenitors undergo specification beneath the surface ectoderm while osteoblast progenitors are specified in a deeper layer of cranial mesenchyme above the eye [2–4]. Subsequently, osteoblast progenitors proliferate and migrate apically beneath the dermal progenitors [1,4]. Both cell types secrete collagen as extracellular matrix, but skull bones provide physical protection for the brain, while the overlying dermis lends integrity to the skin and houses the epidermal appendages [5].

Both paracrine and autocrine intercellular signals function in early bone and skin development. In craniofacial bone formation the mesenchyme sets the timing of ossification [6,7], while the surface ectoderm functions in a permissive manner [8]. Likewise, during skin formation ectodermal signals are essential for formation of the trunk hair-follicle forming dermis [9,10], but the cranial dermal mesenchyme determines epidermal appendage identity such as hair or feather [11]. Further delineation of specific ectoderm-mesenchyme signaling during early development of the

bone and dermis is required to overcome challenges in the engineering of replacement connective tissues.

Mesenchymal canonical Wnt/ β -catenin signal transduction is essential in the specification and morphogenesis of both craniofacial dermis and bone [2,3,12–15], and dysregulation in components of such signaling pathways is associated with diseases of bone and skin [1,2,16–18]. Wntless (*Wls*) functions specifically in trafficking of Wnt ligands and is required for the efficient secretion of Wnt ligands. [2–4,19–28]. Genetic deletion of *Wls* in mice is likely to dramatically reduce the levels of active Wnt ligands and can recapitulate phenotypes obtained by genetic ablation of Wnt ligands in mice [1,4,29]. Wnt ligand binding to target cell surface receptors (Fzd and LRP5/6) results in nuclear translocation of β -catenin, which binds to TCF/LEF transcription factors and activates expression of downstream targets. Certain Wnt ligands also activate the non-canonical Wnt/Planar Cell Polarity (PCP) pathway, which influences cellular movements [5,30,31]. β -catenin is essential in osteoblast differentiation and inhibition of chondrogenesis [6,7,12–14]; however, deletion of individual Wnt ligands resulted only in mild effects on bone differentiation [8,32,33]. β -catenin is also a central regulator of early dermal specification [3,9,10,34,35], and roles for Wnt ligands so far have only been directly shown later during hair

Author Summary

Craniofacial abnormalities are relatively common congenital birth defects, and the Wnt signaling pathway and its effectors have key roles in craniofacial development. *Wntless/Gpr177* is required for the efficient secretion of all Wnt ligands and maps to a region that contains SNPs strongly associated with reduced bone mass, and heterozygous deletion is associated with facial dysmorphism. Here we test the role of specific sources of secreted Wnt proteins during early stages of craniofacial development and obtained dramatic craniofacial anomalies. We found that the overlying cranial surface ectoderm Wnts generate an instructive cue of Wnt signaling for skull bone and skin cell fate selection and transcription of additional Wnts in the underlying mesenchyme. Once initiated, mesenchymal Wnts may maintain Wnt signal transduction and function in an autocrine manner during differentiation of skull bones and skin. These results highlight how Wnt ligands from two specific tissue sources are integrated for normal craniofacial patterning and can contribute to complex craniofacial abnormalities.

follicle initiation [9,11,36]. In bone and skin development, redundant functions of multiple Wnts may compensate for deletion of individual ligands. Conventional knockouts of individual ligands removed Wnt expression from all cells in the embryo, and have confounded the identification of tissue sources of Wnt ligands in bone and skin development. Thus, the relative contributions from different sources of Wnt ligands for fate selection in cranial mesenchyme remain unknown.

Previous limitations were the lack of genetic tools to spatiotemporally manipulate early surface ectoderm and mesenchyme, and an inability to circumvent the intrinsic redundancy of Wnt ligands. We took a conditional approach to ablate the efficient secretion of Wnt ligands from either surface ectoderm or cranial mesenchyme prior to fate selection of the cranial bone and dermal lineages. Our findings provide key insights into how local developmental signals are utilized during morphogenesis to generate the cranial bone and dermal lineages.

Results

We found that the genes for most Wnt ligands were expressed in the cranial mesenchyme (Figure 1A) and surface ectoderm (Figure 1B) during the specification of two separate lineages such as cranial osteoblast and dermal fibroblasts in E12.5 mouse embryos (Figure S1, S7, Table 1). To identify the cells with the potential to secrete Wnt ligands, we examined the spatiotemporal expression of *Wls*, the Wnt ligand trafficking regulator. We detected *Wls* protein expression from E11.5-E12.5 in the cranial surface ectoderm and in the underlying mesenchyme (Figure 1C, G). Both the *Runx2*-expressing cranial bone progenitor domain and the *Derma1/Twist2*-expressing dermal progenitor domain expressed *Wls* [3,37] (Figure 1C, D, E, G). Wnt signaling activation was also visualized in the cranial ectoderm, bone and dermal progenitors by expression of target gene, *Lef1* and nuclear localized β -catenin (Figure 1D, F, H, I). During specification of cranial bone and dermis, ectodermal and mesenchymal tissues secreted Wnt ligands, and the dermal and bone progenitors actively transduced Wnt signaling via β -catenin (Figure 1J).

To dissect the requirements of ectodermal and mesenchymal Wnt signals, we generated mutant mice with conditional deletion of *Wls* [38] in the early surface ectoderm using *Crect* [39] and in

the whole cranial mesenchyme using *Derma1Cre* [40]. *Crect* efficiently recombined the *Rosa26 LacZ Reporter* (RR) in the cranial ectoderm by E11.5 (Figure S4K), but left *Wls* protein expression intact in the mesenchyme (Figure 2A, E, B, F) [41]. *Derma1Cre* recombination showed β -galactosidase activity and *Wls* deletion restricted to the cranial mesenchyme and meningeal progenitors at E12.5, and *Wls* protein was still expressed in the ectoderm in mutants (Figure 2C, D, G, H).

First, we compared the extent to which *Wls* deletion from ectoderm or mesenchyme affected formation of the craniofacial skeleton. E18.5 *Crect; RR; Wls^{f/f}* mutant embryos, which experienced perinatal lethality, demonstrated a hypoplastic face with no recognizable upper or lower jaw most likely due to decrease in cell survival of branchial arch mesenchyme (Figure S5). In the remaining tissue, facial mesenchyme patterning was grossly comparable to controls for most of the markers examined (Figure S5). Notably, the mutants showed no sign of mineralization in the skull vault (Figure 2I–L). The later deletion of *Wls* from the ectoderm using the *Keratin14Cre* line resulted in comparable skull bone ossification as controls (Figure S2). *Derma1Cre; RR; Wls^{f/f}* mutant embryos exhibited lethality after E15.5, which precluded assessment of skeletogenesis by whole-mount. We generated *En1Cre/+; RR; Wls^{f/f}* mutants, using a Cre that recombines in early cranial mesenchyme but lacks activity in meningeal progenitors (Figure S3 E', F') [3]. *En1Cre/+; RR; Wls^{f/f}* mutants survived until birth, and demonstrated reduced bone differentiation and mineralization (Figure S3) as well as intact dermis in the supraorbital region with hair follicles (Figure S3). The more severe arrest in *Crect; RR; Wls^{f/f}* mutants (Figure 2) suggested ectoderm *Wls* appears to play an earlier role than mesenchymal *Wls* in cranial development.

We next examined the effects of ectoderm or mesenchyme *Wls* deletion on cranial bone and dermal development by histology. We found Von Kossa staining for bone mineral was absent in *Crect; RR; Wls^{f/f}* mutants (Figure 3A, B). The thin domain of mesenchyme above the eye in mutants appeared undifferentiated and showed no condensing dermal cells or early stage hair follicles. Additionally, the baso-apical expansion of both dermis and bone was evident by E15.5 in controls, but not in the thin cranial mesenchyme of mutants (Figure 3A–B red arrowhead). Although ossification was absent, we observed the presence of thin nodules of ectopic, alcian blue-stained cartilage (Figure 3E–F). Therefore the result of *Wls* deletion in the ectoderm was an absence of skull ossification and hair-inducing dermis, a failure of baso-apical expansion of mesenchyme, and the presence of ectopic chondrocyte differentiation. By comparison, *Derma1Cre; RR; Wls^{f/f}* mutants showed a reduction in mineralized bone (Figure 3C–D) without ectopic cartilage formation (Figure 3 G–H). The mutant mesenchyme nonetheless condensed and formed sufficient hair-follicle generating dermis in the supraorbital region to support the supraorbital vibrissae hair follicle and fewer primary guard hair follicles (Figure 3 C, D, C', D', black arrowheads). Compared to the control apical region of the head, the mutant lacked sufficient condensed dermal layer to support normal number and differentiation of hair follicles (Fig. 3 C'', D''). Reduced mineralization without ectopic chondrogenesis as well as hair-follicle formation were also present in *En1Cre/+; Wls^{f/f}* mutants (Figure S3). Our data suggest that *Wls* deletion using the *Derma1Cre* resulted in diminished bone mineralization with thinner dermis and fewer hair follicles.

Deletion of *Wls* from the ectoderm resulted in complete absence of skull vault mineralization with failure of dermis formation, pointing to early defects in formation of the two lineages. Therefore we tested if cranial mesenchyme undergoes proper




Figure 1. Expression of Wnt ligands, Wntless, and Wnt signaling response in cranial ectoderm and mesenchyme. (A, B) RT-PCR for individual Wnt ligands was performed on cDNA from purified mouse embryonic cranial mesenchyme and surface ectoderm. (C, D, G, H) Indirect immunofluorescence with DAPI counterstained nuclei (blue), (E) *in situ* hybridization, or immunohistochemistry (F, I) was performed on coronal mouse embryonic head sections. (G, H, I) Boxes indicate region in insets at higher magnification. White arrowheads indicate co-expression of (G) Wls/Runx2 or (D,H) Lef1/Runx2, (I) red arrowheads indicate osteoblast progenitors, and blue arrowheads indicate dermal progenitors. (F–I) White hatched lines demarcate ectoderm from mesenchyme. (J) Summary scheme of E12.5 supraorbital cranial mesenchyme. (J) Embryonic axes, figure depicts lateral view of embryonic head, region of interest in sections used in figures are shown. Scale bars represent 100 μ m.
doi:10.1371/journal.pgen.1004152.g001

patterning, fate selection, and differentiation in the absence of *Wls*. *Msx2* and *Dlx5* that are early markers of skeletogenic patterning in cranial mesenchyme were expressed in *Crect; Wls^{fl/fl}* mutants

(Figures 4A, H, S4). The number of *Msx2*⁺ progenitor cells was not significantly different in controls and mutants (191 ± 9.4 in controls and 206 ± 24 in mutants, P -value = 0.23). However, few

Table 1. Primer sequences for RT-PCR of mouse Wnt genes.

Ligand	Primers	Tm (1 um Primer)	Size	Intron-exon junction	GENEBANK	Coordinates - Dec. 2011 (GRCm38/mm10)
Wnt1 F	ATGAACCTTCACAACAACGAG	59	205	yes	145386529	chr15:98,791,925–98,791,945
Wnt1 R	GGTTGCTGCCTCGGTTG	63				chr15:98,792,568–98,792,584
Wnt2 F	CTGGCTCTGGCTCCCTCTG	64	221	yes	242397431	chr6:18,027,993–18,028,013
Wnt2 R	GGAAGTGGTGTGGCACTCTG	64				chr6:18,030,246–18,030,265
Wnt2b F	CGTTCGTCTATGCTATCTCGTCAG	63	170	no	118130343	chr3:104,953,154–104,953,177
Wnt2b R	ACACCGTAATGGATGTTGCACTAC	62				chr3:104,953,009–104,953,033
Wnt3 F	CAAGCACAACAATGAAGCAGGC	65	200	yes	254028153	chr11:103,811,566–103,811,587
Wnt3 R	TCGGGACTCACGGTGTCTCTC	66				chr11:103,812,431–103,812,451
Wnt3a F	CACCACCGTCAGCAACAGCC	68	119	yes	226958415	chr11:59,275,170–59,275,189
Wnt3a R	AGGAGCGTGTACTGCGAAAG	65				chr11:59,256,477–59,256,497
Wnt4 F	GAGAAGTGTGGCTGTGACCGG	67	80	yes	342672048	chr4:137,295,527–137,295,547
Wnt4 R	ATGTTGTCCGAGCATCCTGACC	66				chr4:137,295,669–137,295,690
Wnt5a F	CTCCTCGCCAGGTTGTTATAG	64	97	yes	371940977	chr14:28,511,918–28,511,940
Wnt5a R	TGCTTCGCACCTTCTCCAATG	66			371940978	chr14:28,513,276–28,513,297
Wnt5b F	ATGCCCGAGAGCGTGAAG	64	128	yes	158321898	chr6:119,440,354–119,440,373
Wnt5b R	ACATTTGCAGCGACATCAGC	64			415702095	chr6:119,433,821–119,433,841
Wnt6 F	TGCCCGAGGCGCAAGACTG	72	130	yes	119672921	chr1:74,782,215–74,782,234
Wnt6 R	ATTGCAAACACGAAAGCTGTCTCTC	66				chr1:74,782,566–74,782,590
Wnt7a F	CTTACTGTCTCTCCAGGATCTTC	64	205	yes	144227223	chr6:91,366,308–91,366,332
Wnt7a R	CGACTGTGGCTGCGACAAG	64				chr6:91,394,575–91,394,593
Wnt 7b F	TCTCTGCTTTGGCGTCTCTAC	64	96	yes	254692921	chr15:85,581,391–85,581,412
Wnt 7b R	GCCAGGCCAGGAATCTTGTG	63			254692925	chr15:85,559,067–85,559,087
Wnt 8a F	ACGGTGGAAATGCTCTGAGCATG	66	106	yes	165972302	chr18:34,542,924–34,542,946
Wnt 8a R	GATGGCAGCAGAGCGGATGG	68				chr18:34,544,809–34,544,828
Wnt 8b F	TTGGGACCGTTGGAATTGCC	68	173	yes	225637541	chr19:44,509,616–44,509,635
Wnt 8b R	AGTCATCACAGCCACAGTTGTC	61				chr19:44,510,510–44,510,531
Wnt 9a F	GCAGCAAGTTTGTCAAGGAGTTCC	66	137	yes	70778750	chr11:59,328,673–59,328,696
Wnt 9a R	GCAGGAGCCAGACACACCATG	67				chr11:59,330,929–59,330,949
Wnt 9b F	AAGTACAGCACCAAGTTCCTCAGC	64	166	yes	238231387	chr11:103,732,048–103,732,071
Wnt 9b R	GAACAGCACAGGAGCCTGACAC	65				chr11:103,731,160–103,731,181
Wnt 10a F	CCTGTTCTCTACTGCTGCTGG	65	200	yes	229094723	chr1:74,792,245–74,792,267
Wnt 10a R	CGATCTGGATGCCCTGGATAGC	68				chr1:74,793,502–74,793,523
Wnt 10b F	TTCTCTCGGATTTCTTGATTC	63	115	yes	274317542	chr15:98,774,188–98,774,210
Wnt 10b R	TGCACTTCCGCTTCAGTTTTTC	66				chr15:98,772,904–98,772,925
Wnt 11 F	CTGAATCAGACGCAACTGTAAC	63		no		chr7:98,846,405–98,846,429
Wnt 11 R	CTCTCTCAGGTCAAGCAGGTAG	63	205		254750613	chr7:98,846,587–98,846,609
Wnt 16 F	AGTAGCGGCACCAAGGAGAC	63	225	yes	255683340	chr6:22,289,022–22,289,029; chr6:22,240,918–22,240,939
Wnt 16 R	GAAACTTCTGCTGAACCATGC	65				chr6:22,291,095–22,291,118

doi:10.1371/journal.pgen.1004152.t001

Runx2⁺ osteoblast progenitors formed in *Crect*; *RR*; *Wls*^{fl/fl} mutant embryos, and expression shifted directly beneath the surface ectoderm (Figure 4B, I). During subsequent differentiation, condensing osteoblast progenitors express alkaline phosphatase (AP; Figure 4C, S4), but ectoderm Wnt-secretion deficient embryos lacked AP activity entirely (Figure 4J, S4). Markers of early osteoblast progenitors from other signaling pathways, *Bmp4* and *PTHrP* (Figure 4D–E, K–L) were also absent in mutants, suggesting an arrest in osteoblast progenitor differentiation. The block was persistent as committed osteoblast

progenitors expressing *Osx* were present in controls but not mutants (Figure 4F, M). Cell survival was not affected in the cranial mesenchyme prior to changes in marker expression (Figure S4A–D). We did not find significant difference in cell proliferation of the underlying mesenchyme (47% ± 4 in controls and 51% ± 2; P-value = 0.12). Whereas chondrocytes expressed *Sox9* only at the skull base in controls, in mutants, ectopic *Sox9*-expressing chondrocyte progenitors and cartilage formed within the frontal bone domain (Figure 4G, N, Q, U). In spite of the effect of ectoderm-*Wls* deletion on mesenchyme, surface ectoderm




Figure 2. Deletion of *Wntless* in the cranial ectoderm and mesenchyme. (A, C, E, G) β -galactosidase staining with eosin counterstain or (B, D, F, H) indirect immunofluorescence with DAPI-stained nuclei (blue) was performed on coronal mouse E12.5 head sections. (A–H) Box outlines indicate region in inset and white hatched line in insets demarcates cranial ectoderm from mesenchyme. (I–L) Lateral view of whole-mount skeletal preps or gray-scaled bright field images of embryonic mouse heads. Ey, eye. Scale bars for sections represent 100 μ m. Scale bar (K) for whole mount pictures (I–L) represents 5 mm. Diagram inset in (D) depicts lateral view of embryonic head with box outlining region of interest. doi:10.1371/journal.pgen.1004152.g002

expression of the differentiation marker, Keratin 14 (K14) was unaffected (Figure S4E,F). Next, we examined formation of dermal fibroblast progenitors in *Crect; RR; Wls^{fl/fl}* mutant embryos. Cranial dermal fibroblast progenitors expressed the markers, *Twist2* [3,37] and Insulin Growth factor 2 (IGF2) by E12.5 in supraorbital mesenchyme (Figure 4O, P), but mutant embryos

lacked *Twist2* and IGF2 expression (Figure 4S, T). *Twist2* expression became more progressively restricted to upper dermal fibroblasts during differentiation in controls, but was completely absent from cranial supraorbital mesenchyme of mutants (Figure 4R, V). The altered cell fate marker expression at E12.5 (Figure 4, S4 I, J) immediately after deletion of ectoderm *Wls* (Figure S4K)




Figure 3. Distinct requirements for *Wntless* in the cranial ectoderm and mesenchyme. (A, B, C, D, C', D') Von Kossa staining, or (E–H) alcian blue staining was performed on coronal mouse embryonic head sections and counterstained with eosin. Br, brain, fb, frontal bone, vhf, supraorbital vibrissae hair follicle, mn, meningeal progenitors. Black arrowheads indicate guard hair follicles (hf), red arrowheads indicate dorsal extent of ossified frontal bone, and open black arrows indicate ectopic cartilage. (C', D', C'', D'') Black dotted line demarcates the lower limit of the dermal layer and the black bracket shows dermal thickness. Diagrams inset (B) figure depicts lateral view of E15.5 embryonic head with plane of section and region of interest. Red regions in diagram represent bone primordia. Scale bars (A,E) represent 100 μ m. doi:10.1371/journal.pgen.1004152.g003

was indicative of primary defects in mesenchymal cell fate selection. Together, our data suggest ectoderm Wnts form a non-cell autonomous inductive signal to the underlying mesenchyme for specification of osteoblast and dermal fibroblast progenitors, and for repression of chondrogenesis.

Next, we determined if mesenchyme *Wls* deletion resulted in a later defect in differentiation of cranial bone and dermal fibroblast progenitors. In *En1Cre; RR; Wls^{fl/fl}* mutants, *Runx2* expression in osteoblast progenitors was intact without ectopic *Sox9* expression, but showed diminished expression of the skeletal differentiation marker, *Osx* and ossification (Figure S3). Wnt responsiveness by *Axin2* expression was comparable in control and mutant cranial mesenchyme at E14.5 (Figure S3). In *Dermo1Cre; RR; Wls^{fl/fl}* mutants, *Runx2* expression was also unaffected during fate selection stages (Figure 5A, G, B, H). However, during later osteoblast progenitor differentiation (E15.5), *Osx* was diminished in mutants at E15.5 (Figure 5C, I). In dermal progenitors undergoing specification, *Twist2* expression was unaffected (Figure 5D, J), and surface ectoderm differentiation marker, K14, was appropriately expressed (Figure S6C, D). Additionally at later stages in the mutant, we observed thinner dermis, which was sufficient to support initiation of fewer guard hair follicles (data not shown) and supraorbital vibrissae hair follicle formation (Figs. 3C, D; 5E, K). Furthermore, no ectopic expression of *Sox9* occurred in mesenchyme *Wls*-deficient mutants (Figs. 5F, L). Deletion of mesenchyme-*Wls* did not lead to decrease in cell survival as monitored by expression of activated-Caspase3 (Figure S6A–B). Prior to E15.5, cell proliferation of osteoblast, dermal, and surface ectoderm progenitors was not significantly different from controls (Figure S6). Based on *Dermo1Cre*- and *En1Cre*- deletion of *Wls*, mesenchyme-derived Wnt ligands are not required for

differentiation of dermal progenitors but are indispensable for later differentiation of osteoblast progenitors. Next, we tested the spatiotemporal requirement for mesenchyme *Wls* in Wnt signaling transduction. Nuclear β -catenin and *Axin2* expression were comparable in the mesenchyme of mutants during fate selection stages at E12.5 (Figure 5M, N, Q, R). As differentiation occurs, expression of *Axin2* and *Lef1* was selectively diminished in the osteoblast progenitor domain of mesenchyme-*Wls* mutants compared to the controls (Figure 5O, P, S, T). Thus, mesenchyme Wnt ligands appeared to be important in mesenchyme Wnt signal transduction during osteoblast differentiation and ossification as opposed to earlier lineage specification events.

Next, we examined the source of Wnts for the onset of Wnt responsiveness in the mesenchyme. During dermal and osteoblast progenitor cell fate selection, Wnt ligands, inhibitors, and target genes are expressed in spatially segregated patterns. *Wnt10a* and *Wnt7b* were expressed in surface ectoderm (Figure 6A–B), *Wnt11* was expressed in sub-ectodermal mesenchyme (Figure 6C), and *Wnt16* mRNA was expressed in medial mesenchyme (Figure 6D). Notably, the soluble Wnt inhibitor, *Dickkopf2* (*Dkk2*) mRNA was localized to the deepest mesenchyme overlapping with cranial bone progenitors (Figure 6E). Wnt ligands can induce nuclear translocation of β -catenin in a dose-dependent manner leading to the expression of early target genes [42,43]. At E11.5, expression of nuclear β -catenin was present in both dermal and osteoblast progenitors, and the highest intensity of nuclear localization was found in the surface ectoderm and dermal mesenchyme (Figure 1F). Wnt target genes *Lef1*, *Axin2*, and *TCF4* were patterned in partially complementary domains. Expression of *Tcf4* protein was visible in the skeletogenic mesenchyme (Figure 6F). *Tcf4* expression expanded into the mesenchyme under the




Figure 4. Ectoderm deletion of *Wntless* leads to loss of cranial bone and dermal lineage markers in the mesenchyme. Indirect immunofluorescence with DAPI-stained (blue) nuclei was performed on coronal mouse embryonic head sections at E12.5 or as indicated (A,B, F, G, H, I, M, N, P, R, T, V). Alkaline Phosphatase staining (C, J), in situ hybridization (D, E, K, L, O, S), or β -galactosidase staining with eosin counterstain (Q, U) was performed on coronal tissue sections. Diagram in (A) demonstrates plane of section and region of interest for E12.5-E13.5 (A–T). Box and dashed lines in (Q, U) demonstrate the region of high magnification, and β -galactosidase stained sections were included for perspective for (R, V). Diagram inset in high magnification photograph from (Q) shows plane of section and region of interest for E15.5. Red arrows indicate changes in marker expression and black arrows in (U) high magnification indicate ectopic cartilage. Scale bars represent 100 μ m.
doi:10.1371/journal.pgen.1004152.g004

ectoderm in ectoderm *Wls*-deficient mutants (Figure 6I–J) and was diminished in mesenchyme *Wls*-deficient mutants compared to controls (Figure 6K–L). *Lef1* and *Axin2* were expressed at the highest intensity in the dermal progenitors beneath the ectoderm (Figure 6 G, H). At E12.5, *Lef1* expression was completely abolished in the mesenchyme of ectoderm-*Wls* mutants, but was comparable to controls in the absence of mesenchyme-*Wls* (Figure 6M–P). The onset of Wnt signaling response in the mesenchyme as measured by *Lef1*, *Axin2*, and nuclear β -catenin expression (Figure 6O–T) required ectoderm *Wls*. By contrast, no single tissue source of Wnt ligands was required to maintain *TCF4* expression.

Finally, we tested whether cranial surface ectoderm Wnt ligands regulate the onset of Wnt ligand mRNA expression in the underlying mesenchyme (Figure 7). The non-canonical ligands *Wnt5a* and *Wnt11* were expressed in cranial mesenchyme, with the highest expression corresponding to dermal progenitors. *Wnt4*, which signals in canonical or non-canonical pathways [44], was expressed strongly in dermal progenitors, as well as in osteoblast

progenitors and in the skull base (Figure 7A–C). *Wnt3a* and 16, which signal in the canonical pathway via β -catenin and have roles in intramembranous bone formation, were expressed medially in the cranial mesenchyme containing cranial bone progenitors (Figure 7D, E) [12–14,45]. Expression of *Wnt5a*, *Wnt11*, *Wnt3a*, *Wnt16* mRNAs was absent from the mesenchyme of *Cre; RR; Wls^{β/β}* mutants whereas some *Wnt4* expression was maintained (Fig. 7F–J). *En1Cre* deletion of β -catenin in the cranial mesenchyme [12] also resulted in an absence of *Wnt5a* and *Wnt11* expression, except in a small portion of supraorbital lineage-labeled mesenchyme, suggesting a phenocopy of *Cre; Wls* mutants (Figure 7K, L, M). In contrast, *Wnt5a*, *Wnt11*, and *Wnt4* expression were present in the *Dermo1Cre; RR; Wls^{β/β}* mutants (Figure 7N–S). However, the Wnt-expressing domains were smaller and only located close to the surface ectoderm, but nonetheless were lineage-labeled (Figure 7E–G, L–N; not shown). Thus, consistent with a role as initiating factors, ectoderm Wnt ligands and mesenchyme β -catenin were required for expression of certain Wnt ligands in the cranial mesenchyme during lineage selection.




Figure 5. Mesenchyme deletion of *Wntless* leads to diminished differentiation and Wnt responsiveness in the bone lineage. Indirect immunofluorescence with DAPI-stained (blue) nuclei (A, B, D, F, G, H, J, L, P, T) and immunohistochemistry (M, Q) was performed on coronal mouse embryonic head sections. In situ hybridization (C, I, N, O, R, S) or eosin counterstain (E, K), was performed on coronal tissue sections of embryonic murine heads at the indicated stages. Diagram in (A) demonstrates plane of section and region of interest for E11.5–E12.5. Box in (D, J) demonstrate the region of high magnification. (I, S, T) Red arrows highlight changes in marker expression in osteoprogenitor domain. (E, K) vhf: suborbital vibrissae hair follicle and black bracket indicates the dermal layer. (A, G) Scale bars represent 100 μ m. doi:10.1371/journal.pgen.1004152.g005

Mesenchymal Wnt ligands may in turn be required later for osteoblast differentiation (Figure 7T).

Discussion

Here we obtained data suggesting that ectodermal and mesenchymal Wnts function distinctly in early dermal and osteoblast progenitor specification and differentiation. Wnt ligands are expressed in the cranial surface ectoderm and mesenchyme, and ectoderm Wnts are required to generate an inductive cue for the specification of multiple lineages in the cranial mesenchyme. The dermal progenitors and osteoblast progenitors closest to the ectoderm experience the highest concentrations of nuclear β -catenin, in response to Wnt ligands from overlying ectoderm. Subsequent differentiation of osteoblast and dermal fibroblast

progenitors requires *Wls* from the mesenchyme. Thus our study demonstrates that two different sources of Wnt signals coordinate to form two separate lineages, bone and dermis.

We present evidence to demonstrate that ectoderm Wnts generate an inductive cue of Wnt signaling in the mesenchyme to specify cranial bone and dermal lineages. The mechanism remains elusive; however, there are at least three possible models. First, the spatial segregation of Wnt pathway transcription cofactors such as Lef1 and TCF4, partially by lineage, provides a mechanism to generate different lineage programs. Second, a threshold-dependent model may also exist to generate multiple lineages from the same signal. At E11.5–12.5, dermal progenitors are closest to the ectoderm Wnt source and exhibit the highest Wnt signaling reporter activity and markers induced by constitutive activation of β -catenin in mesenchyme (Figure 1) [3,9,46]. High levels of Wnt




Figure 6. Generation of Wnt responsiveness in the cranial mesenchyme. In situ hybridization (A–E, H, Q, R), immunohistochemistry (S, T) or indirect immunofluorescence with DAPI-stained nuclei (blue) was performed on coronal mouse embryonic head sections (F, G, I–P). (S, T) White dotted line demarcates ectoderm from mesenchyme. Embryonic head diagram depicts region of interest and plane of section. Embryonic axes for the sections are presented. Scale bars represent 100 μm .
doi:10.1371/journal.pgen.1004152.g006

pathway activity preclude osteoblast marker expression in the mesenchyme [12]. Consistently, osteoblast progenitors are present farther away from the ectoderm in an overlapping domain to at least one Wnt inhibitor, *Dkk2* [47] (Figure 6E). Finally, the osteoblast response to ectodermal Wnts may be indirect; osteoblast progenitors may require a separate signal relayed from dermal progenitors. Future genetic experiments with new reagents will be required to distinguish between these models and test direct or indirect requirements of Wnt sources in osteoblast and dermis formation.

During fate selection of cranial dermal and osteoblast progenitors, upstream ectodermal Wnt ligands initiate expression of a subset of mesenchymal Wnt ligands via β -catenin. Ectoderm Wnts also act upstream of mesenchyme Wnts in mouse limb development [48]. Here, ectoderm Wnts act in a temporally earlier role than mesenchyme Wnts, and other studies support a direct relationship. In at least one instance, mesenchyme Wnt ligands are direct targets of canonical Wnt signaling [49]. Alternatively, ectoderm and mesenchyme Wnts may signal in parallel pathways

to the mesenchyme. The signal that acts upstream to initiate Wnt ligand expression in the cranial ectoderm remains unknown.

We report here that osteoblast differentiation requires distinct Wnt signals from surface ectoderm and mesenchyme. β -catenin deletion in the ectoderm did not inhibit skull bone mineralization [39], so autocrine effects of *Wls* deletion on the ectoderm were unlikely to contribute to the skull phenotype. However, removal of surface ectoderm *Wls* resulted in ectopic chondrogenesis (Figure 3), which phenocopied mesenchymal β -catenin deletion [12]. In contrast, mesenchymal *Wls* deletion did not result in ectopic cartilage formation, suggesting repression of chondrogenesis in cranial mesenchyme requires an early, ectoderm Wnt signal. Our results thus implicate β -catenin here as a Wnt pathway factor that acts in the nucleus to repress chondrogenesis and functions downstream of ectoderm ligands. Ectoderm Wnt ligands thus provide an inductive cue acting on osteoblast progenitors while the cells are closest to the ectoderm. Indeed, later deletion of *Wls* from the ectoderm using the K14Cre line did not give rise to a skull bone ossification phenotype (Figure S2). During osteoblast




Figure 7. Mesenchyme Wnt ligand expression is dependent on ectoderm *Wls* and mesenchymal β -catenin. (A–S) *In situ* hybridization was performed on coronal mouse embryonic head sections. Diagram of embryonic head in (A) inset depicts region of interest and plane of section. Insets in (K, L) show β -galactosidase staining and eosin counterstaining on serial sections. (T) A working model for role of tissue sources of Wnt ligands during cranial mesenchymal lineage fate selection. Scale bars represent 100 μ m. doi:10.1371/journal.pgen.1004152.g007

progenitor differentiation, *Wls* deletion with *Dermo1Cre* resulted in a similar but more severe differentiation arrest than the more restricted *En1Cre*. Consistently, using a different *Wls* mutant allele, deletion of mesenchymal Wnts led to absence of osteoblast differentiation expression and reduced cell proliferation [50]. We show that the mesenchyme Wnts maintain the differentiation process but require an inductive ectoderm Wnt signal.

We demonstrate that dermal progenitors require ectodermal *Wls* for specification and mesenchymal *Wls* for normal differentiation (Figs. 4–5). Cranial dermal progenitors located beneath the ectoderm require β -catenin for specification [3], but the tissue contribution of Wnt sources remained previously undetermined. Here, a mesenchymal *Wls* source is indispensable in the dermal lineage for normal differentiation, thickness, and hair follicle patterning. Previous reports in murine trunk skin development suggested that ectoderm Wnts alone are essential in hair follicle induction [9,10]. Differential requirements may exist for mesoderm-derived trunk dermal progenitors and cranial neural crest-derived dermal progenitors. Future studies will be needed to uncover the requirements for a mesenchymal Wnt signal in dermal fibroblast differentiation in different parts of the embryo.

Conditional *Wls* deletion resulted in a failure of cranial dermal and osteoblast progenitors to undergo baso-apical extension (Figure 3), a process that occurs independently of β -catenin [12]. Since *Wls* deletion blocked secretion of canonical and non-canonical Wnt ligands, extension defects in the mesenchyme are consistent with known roles for non-canonical Wnt ligands in orienting cell movements [51]. Homozygous null mutants of core planar cell polarity (PCP) components lacked proper skull tissue development and neural tube closure [52]. However, mutants for individual non-canonical Wnt ligands lack a cranial PCP phenotype. In the cranial mesenchyme, non-canonical Wnt5a or Wnt11 ligands were expressed in overlapping expression domains, suggesting the ligands function redundantly [53] (Figure 7). Therefore, the role of PCP signaling remains to be rigorously tested in conditional mutant mice. The non-canonical and canonical Wnt signaling pathways interact extensively. In our study, canonical β -catenin transduction, in response to ectodermal Wnts, initiates non-canonical Wnt ligand expression (Figure 7), consistent with reports from other systems [30,49,51]. Our results reinforce the role of non-canonical Wnt ligands in the pathogenesis of craniofacial anomalies [54,55]. The ability of exogenous

non-canonical Wnts to compensate for *Wls* deletion in the baso-apical extension of dermal and osteoblast progenitors remains to be tested.

Our results from tissue-specific deletion of *Wls* have implications in diseases with dysregulation of dermal fibroblasts or osteoblasts, and in understanding the pathogenesis of craniofacial birth defects. Removal of *Wls* from the ectoderm by E12.5 of mouse development reveals a default state for formation of cartilage in the cranial skeleton and dermis if all Wnt secretion were absent from the ectoderm. This forms an important baseline state that can be used to interpret less severe genetic conditions resulting from loss or mutation of individual Wnt ligands. In this respect, we hypothesize that mutations in the Wnt secretory pathway may underlie diseases of osteoblasts, and dermal fibroblasts, warranting continued investigation into the role of Wnt production in bone and skin formation and homeostasis [15,17,18,45,56–58]. Understanding the signals surrounding osteoblast and dermal fibroblast formation is crucial to meet the demands of engineering appropriate connective tissues.

Materials and Methods

Mice and genotyping

Conditional functional studies were conducted using *Crect*, *Keratin 14Cre*; *Dermo1Cre*, *En1Cre*, β -catenin deleted, conditional β -catenin floxed mice [39,40,59–62]. Mice and embryos were genotyped as described previously. The conditional loss-of-function floxed allele for *Wls* (*Wls*^{fl/fl}) was described previously [38]. RR/RR mice harboring a *LacZ* transgene downstream of a floxed stop transcription signal in the ubiquitous *Rosa26* locus were obtained for lineage tracing [41]. For timed matings the vaginal plug day was assigned as E0.5. At desired time points, embryos were harvested and processed for frozen sections as previously described [34]. For each experiment, at least three to five different mutants with littermate controls from 2–3 litters were analyzed. At least three to five litters were used for all analyses. Case Western Reserve Institutional Animal Care and Use Committee approved all animal procedures.

In situ hybridization, immunohistochemistry, and histology

Embryos were fixed in 4%PFA, cryopreserved, and sectioned at 8–12 μ m. In situ hybridization, β -galactosidase with eosin counter-staining, and immunohistochemistry were performed essentially as described [34,35]. Alcian blue staining of sections was performed as described. For Von Kossa staining of frozen sections, slides were fixed with 4% PFA, incubated in the dark with 2% silver nitrate, rinsed, exposed to light, and counterstained with eosin. In situ probes for *Twist2* (Eric Olson, Dallas, TX), *Pthrp*, *Wnt4* (V. Lefebvre, Cleveland, OH), *Wnt5a* (Andrew McMahon, Boston, MA), *Wnt11* (Steve Potter, Cincinnati, OH), *Axin2* (Brian Bai), *BMP4*, *Wnt7b*, *Dlx5* (Gail Martin, San Francisco, CA), *Wnt16* (Yingzi Yang, Bethesda, MD) and *Osx* (Matthew Warmann, Boston, MA) were gifts. For *Wnt10a*, cDNA was amplified from E12.5 RNA using primer F: GCTATTTAGGTGACACTA-TAGGCGCTCTGGGTAAACTGAAG, primer R: TTGTAA-TACGACTCACTATAGGGAGAGCCAACCACCTCTCTCA, and in vitro transcription of antisense mRNA with T7 polymerase. For *Dkk2*, PCR primers *DKK2-F*(5'-GACATGAAGGAGACC-CATGCCTACG-3' and *DKK2-T7R* 5'-TGTAATACGACTC-ACTATAGGGCATAGATGAGGCACATAACGGAAG-3' were used.

Primary antibodies for Runx2, Sox9, Twist2, Lef1, Osx, Msx2, Ki67, IGF2, *Wls*, and β -catenin (goat anti-Runx2; 1:20, R&D

Biosystems; rabbit anti-Sox9; 1:100; Millipore; mouse anti-Twist2, 1:500, Santa Cruz; rabbit anti-Lef1, 1:100, Abcam; rabbit anti-Osx, 1:400, Abcam; mouse Msx1/2, 1:50, DSHB; activated Caspase3, 1:250, Abcam; rabbit Ki67; 1:500 Abcam; rabbit IGF2 1:400, Cell Signaling); rabbit anti-*Wls*, 1:2000, gift from Richard Lang; mouse β -catenin 1:100 BD Biosciences) were used for indirect immunofluorescence and immunohistochemistry. All control/mutant pairs were photographed at the same magnification. Number of *Msx2*⁺ cells was counted from a fixed field in 10 different sections from 4 embryos.

Proliferation index was assessed by percent of cells with Ki67 expression in the Runx2 expression domain, in the dermal mesenchyme in the Twist2 domain, and surface ectoderm in the Keratin14 expressing cells. Similar numbers of cells in each domain were analyzed between four controls and mutants. Statistical significance for all quantifications was calculated using two-tailed Student *t*-test.

Alcian blue and Alizarin red and AP staining

Embryos were sacrificed, skinned and eviscerated, fixed in 95% ethanol, then stained for 24 hours each in 0.03% Alcian blue and 0.005% Alizarin red. Stained embryos were subsequently cleared in graded series of potassium hydroxide and glycerol until photography, after which they were stored in 0.02% Sodium Azide in glycerol. Whole mount Alkaline phosphatase staining was performed as previously described [63] with the addition of a 70% ethanol overnight incubation step after fixation in 4% PFA.

RT-PCR

Cranial mesenchyme and surface ectoderm were micro-dissected from E12.5 embryos and flash frozen in liquid nitrogen. Total RNA was isolated using the Qiagen RNEasy micro kit, and cDNA was reverse transcribed using the ABI kit. RT-PCR for most of the Wnt ligands was amplified for 35 cycles of 94°C for 15 seconds, 66°C for 30 seconds, and 72°C for 60 seconds and the products were resolved on a 3% agarose gel. For *Wnt1*, 5b, 8a, 8b, 10b the annealing temperature was 55°C for 30 seconds. Primer sequences for RT-PCR are listed in Table 1.

Supporting Information

Figure S1 Expression of Wnt ligands in total cranial ectoderm and mesenchyme. (A) RT-PCR for individual Wnt ligands was performed on cDNA from purified mouse embryonic cranial mesenchyme and surface ectoderm. (B) –RT negative control. (EPS)

Figure S2 Later deletion of *Wls* in the ectoderm is dispensable for cranial bone ossification. (A,B) Whole-mount skeletal preps of embryonic mouse heads. P, parietal bone, f, frontal bone, n, nasal bone, ey, eye, mx, maxilla. Scale bar represents 5 mm. (EPS)

Figure S3 Mesenchymal deletion of *Wntless* with *Engrailed1Cre* leads to diminished bone differentiation. (A–D) Whole-mount skeletal preps of embryonic mouse heads. P, parietal bone, f, frontal bone, n, nasal bone, ey, eye, mx, maxilla. Scale bar represents 5 mm. Indirect immunofluorescence with DAPI-stained (blue) nuclei (G, K, M, Q) or in situ hybridization (H, I, N, O) was performed on E13.5 coronal embryonic head sections. β -galactosidase staining (E, F, E', F'), Von Kossa staining (J, P), or alcian blue staining (L, R) was performed on coronal embryonic head sections and counterstained with eosin at the indicated stages. fb, forebrain, mn, meningeal progenitors, vhf, supraorbital vibrissae hair follicle. Green arrowheads indicate meningeal

progenitors, black arrowheads indicate hair follicles, and red arrow demarcates the dorsal extent of ossified frontal bone. High magnification images (E', F') with accompanying low magnification and box depicting inset (E, F). Control and mutant panels are shown at the same magnification and scale bars represent 100 μm . (EPS)

Figure S4 Deletion of ectoderm *Wntless* does not compromise cell survival and ectodermal differentiation. Indirect immunofluorescence with DAPI-stained (blue) nuclei (A–F), in situ hybridization (G, H), β -gal staining (K) was performed on coronal embryonic head sections. E12.5 embryonic heads were stained in whole mount for AP activity to detect bone primordia (black arrow in I, J). Note that in the *Creech; Wls^{fl/fl}* mutant, the frontal bone rudiment is not detectable (red arrows in J). Inset in A, shows positive control for active caspase 3 immunostaining in the developing eye. Diagram of embryonic head in (A) inset depicts region of interest and plane of section. Boxed areas correspond to high magnification panels (E, F, E', F') and white-hatched lines demarcate the surface ectoderm (E', F'). Fb, frontal bone; pb, parietal bone, cs coronal suture. (EPS)

Figure S5 Deletion of ectoderm *Wntless* leads to decrease in cell survival of brachial arch mesenchyme but not patterning. In situ hybridization of various facial mesenchyme patterning markers (A–H) and indirect immunofluorescence of activate caspase 3 with DAPI stained nuclei to identify dying cells (I, J) was performed on

coronal E12.5 head sections. Diagram of embryonic head in (A) inset depicts region of interest and plane of section. (EPS)

Figure S6 Deletion of mesenchyme *Wntless* does not compromise cell survival, ectoderm differentiation, and proliferation. Indirect immunofluorescence with DAPI stained nuclei (A–D). Percentage of Ki67+ proliferating cells in the osteoprogenitors, dermal progenitors and surface ectoderm at E12.5 and E13.5 (E). Boxed areas correspond to high magnification panels (C', D'). (EPS)

Figure S7 Cranial dermal and osteoprogenitors are distinct lineages during embryonic development. Indirect immunofluorescence with DAPI stained nuclei (A–C). Boxed areas correspond to high magnification panels (A'–C'). (EPS)

Acknowledgments

We thank R.P.A. lab members for technical assistance and discussion. We thank Samantha Brugmann and Veronique Lefebvre for critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: LHG RPA. Performed the experiments: LHG GJD JWF. Analyzed the data: LHG RPA. Contributed reagents/materials/analysis tools: TW RAL. Wrote the paper: LHG RPA.

References

- Jiang X (2002) Tissue Origins and Interactions in the Mammalian Skull Vault. *Developmental Biology* 241: 106–116.
- Hsu Y-H, Zillikens MC, Wilson SG, Farber CR, Demissie S, et al. (2010) An integration of genome-wide association study and gene expression profiling to prioritize the discovery of novel susceptibility Loci for osteoporosis-related traits. *PLoS Genet* 6: e1000977.
- Tran TH, Jarrell A, Zentner GE, Welsh A, Brownell I, et al. (2010) Role of canonical Wnt signaling/ β -catenin via Dermo1 in cranial dermal cell development. *Development* 137: 3973–3984.
- Yoshida T, Vivatbutisiri P, Morriss-Kay G, Saga Y, Iseki S (2008) Cell lineage in mammalian craniofacial mesenchyme. *Mechanisms of Development* 125: 797–808.
- Hardy MH (1992) The secret life of the hair follicle. *Trends Genet* 8: 55–61.
- Schneider RA, Helms JA (2003) The cellular and molecular origins of beak morphology. *Science* 299: 565–568.
- Merrill AE, Eames BF, Weston SJ, Heath T, Schneider RA (2008) Mesenchyme-dependent BMP signaling directs the timing of mandibular osteogenesis. *Development* 135: 1223–1234.
- Hall BK (1981) The induction of neural crest-derived cartilage and bone by embryonic epithelia: an analysis of the mode of action of an epithelial-mesenchymal interaction. *J Embryol Exp Morphol* 64: 305–320.
- Chen D, Jarrell A, Guo C, Lang R, Atit R (2012) Dermal β -catenin activity in response to epidermal Wnt ligands is required for fibroblast proliferation and hair follicle initiation. *Development* 139: 1522–1533.
- Fu J, Hsu W (2012) Epidermal Wnt Controls Hair Follicle Induction by Orchestrating Dynamic Signaling Crosstalk between the Epidermis and Dermis. *Journal of Investigative Dermatology* 133: 890–898.
- Eames BF, Schneider RA (2005) Quail-duck chimeras reveal spatiotemporal plasticity in molecular and histogenic programs of cranial feather development. *Development* 132: 1499–1509.
- Goodnough LH, Chang AT, Treloar C, Yang J, Scacheri PC, et al. (2012) Twist1 mediates repression of chondrogenesis by β -catenin to promote cranial bone progenitor specification. *Development* 139: 4428–4438.
- Day T, Guo X, Garrettbeal L, Yang Y (2005) Wnt/ β -Catenin Signaling in Mesenchymal Progenitors Controls Osteoblast and Chondrocyte Differentiation during Vertebrate Skeletogenesis. *Dev Cell* 8: 739–750.
- Hill T, Spater D, Taketo M, Birchmeier W, Hartmann C (2005) Canonical Wnt/ β -Catenin Signaling Prevents Osteoblasts from Differentiating into Chondrocytes. *Dev Cell* 8: 727–738.
- Zhong Z, Zylstra-Diegel CR, Schumacher CA, Baker JJ, Carpenter AC, et al. (2012) Wntless functions in mature osteoblasts to regulate bone mass. *Proceedings of the National Academy of Sciences* 109: E2197–E2204.
- Richards JB, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, et al. (2008) Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. *Lancet* 371: 1505–1512.
- Wang X, Reid Sutton V, Omar Peraza-Llanes J, Yu Z, Rosetta R, et al. (2007) Mutations in X-linked PORCN, a putative regulator of Wnt signaling, cause focal dermal hypoplasia. *Nat Genet* 39: 836–838.
- Rivadeneira F, Styrkarsdottir U, Estrada K, Halldórsson BV, Hsu Y-H, et al. (2009) Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. *Nat Genet* 41: 1199–1206.
- Bänziger C, Soldini D, Schütt C, Zipperlin P, Hausmann G, et al. (2006) Wntless, a conserved membrane protein dedicated to the secretion of Wnt proteins from signaling cells. *Cell* 125: 509–522.
- Bartscherer K, Pelte N, Ingelfinger D, Boutros M (2006) Secretion of Wnt ligands requires Evi, a conserved transmembrane protein. *Cell* 125: 523–533.
- Fu J, Jiang M, Mirando AJ, Yu HM, Hsu W (2009) Reciprocal regulation of Wnt and Gpr177/mouse Wntless is required for embryonic axis formation. *Proceedings of the National Academy of Sciences* 106: 18598–18603.
- Goodman RM, Thombre S, Firtina Z, Gray D, Betts D, et al. (2006) Sprinter: a novel transmembrane protein required for Wg secretion and signaling. *Development* 133: 4901–4911.
- Belenkaya TY, Wu Y, Tang X, Zhou B, Cheng L, et al. (2008) The retromer complex influences Wnt secretion by recycling wntless from endosomes to the trans-Golgi network. *Dev Cell* 14: 120–131.
- Franch-Marro X, Wendler F, Guidato S, Griffith J, Baena-Lopez A, et al. (2008) Wingless secretion requires endosome-to-Golgi retrieval of Wntless/Evi/Sprinter by the retromer complex. *Nat Cell Biol* 10: 170–177.
- Port F, Kuster M, Herr P, Furger E, Bänziger C, et al. (2008) Wingless secretion promotes and requires retromer-dependent cycling of Wntless. *Nat Cell Biol* 10: 178–185.
- Port F, Basler K (2010) Wnt trafficking: new insights into Wnt maturation, secretion and spreading. *Traffic* 11: 1265–1271.
- Yang P-T, Lorenowicz MJ, Silhankova M, Coudreuse DYM, Betist MC, et al. (2008) Wnt signaling requires retromer-dependent recycling of MIG-14/Wntless in Wnt-producing cells. *Dev Cell* 14: 140–147.
- Das S, Yu S, Sakamori R, Stypulkowski E, Gao N (2012) Wntless in Wnt secretion: molecular, cellular and genetic aspects. *Front Biol (Beijing)* 7: 587–593.
- Fu J, Ivy Yu H-M, Maruyama T, Mirando AJ, Hsu W (2011) Gpr177/mouse Wntless is essential for Wnt-mediated craniofacial and brain development. *Dev Dyn* 240: 365–371.
- van Amerongen R, Nusse R (2009) Towards an integrated view of Wnt signaling in development. *Development* 136: 3205–3214.
- Clevers H, Nusse R (2012) Wnt/ β -catenin signaling and disease. *Cell* 149: 1192–1205.
- Spater D, Hill TP, O'Sullivan R J, Gruber M, Conner DA, et al. (2006) Wnt9a signaling is required for joint integrity and regulation of Ihh during chondrogenesis. *Development* 133: 3039–3049.

33. Bennett CN, Longo KA, Wright WS, Suva IJ, Lane TF, et al. (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. *Proc Natl Acad Sci USA* 102: 3324–3329.
34. Atit R, Sgaier SK, Mohamed OA, Taketo MM, Dufort D, et al. (2006) Beta-catenin activation is necessary and sufficient to specify the dorsal dermal fate in the mouse. *Developmental Biology* 296: 164–176.
35. Ohtola J, Myers J, Akhtar-Zaidi B, Zuzindlak D, Sandesara P, et al. (2008) beta-Catenin has sequential roles in the survival and specification of ventral dermis. *Development* 135: 2321–2329.
36. Hu B, Lefort K, Qiu W, Nguyen B-C, Rajaram RD, et al. (2010) Control of hair follicle cell fate by underlying mesenchyme through a CSL-Wnt5a-FoxN1 regulatory axis. *Genes & Development* 24: 1519–1532.
37. Li L, Cserjesi P, Olson EN (1995) Dermo-1: a novel twist-related bHLH protein expressed in the developing dermis. *Developmental Biology* 172: 280–292.
38. Carpenter AC, Rao S, Wells JM, Campbell K, Lang RA (2010) Generation of mice with a conditional null allele for Wntless. *genesis* 48: 554–558.
39. Reid BS, Yang H, Melvin VS, Taketo MM, Williams T (2011) Ectodermal Wnt/beta-catenin signaling shapes the mouse face. *Developmental Biology* 349: 261–269.
40. Yu K (2003) Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. *Development* 130: 3063–3074.
41. Soriano P (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. *Nat Genet* 21: 70–71.
42. Willert K, Brown JD, Danenberg E, Duncan AW, Weissman IL, et al. (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors. *Nature* 423: 448–452.
43. Rudloff S, Kemler R (2012) Differential requirements for beta-catenin during mouse development. *Development* 139: 3711–3721.
44. Lyons JP, Mueller UW, Ji H, Everett C, Fang X, et al. (2004) Wnt-4 activates the canonical beta-catenin-mediated Wnt pathway and binds Frizzled-6 CRD: functional implications of Wnt/beta-catenin activity in kidney epithelial cells. *Exp Cell Res* 298: 369–387.
45. Zheng HF, Tobias JH, Duncan E, Evans DM, Eriksson J, et al. (2012) WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk. *PLoS Genet* 8: e1002745.
46. Mani P, Jarrell A, Myers J, Atit R (2010) Visualizing canonical Wnt signaling during mouse craniofacial development. *Dev Dyn* 239: 354–363.
47. Fjeld K, Kettunen PI, Furmanek T, Kvinnsland IH, Luukko K (2005) Dynamic expression of Wnt signaling-related Dickkopf1, -2, and -3 mRNAs in the developing mouse tooth. *Dev Dyn* 233: 161–166.
48. Zhu X, Zhu H, Zhang L, Huang S, Cao J, et al. (2012) Wls-mediated Wnts differentially regulate distal limb patterning and tissue morphogenesis. *Developmental Biology*: 1–11.
49. Zhou W, Lin L, Majumdar A, Li X, Zhang X, et al. (2007) Modulation of morphogenesis by noncanonical Wnt signaling requires ATF/CREB family-mediated transcriptional activation of TGFbeta2. *Nat Genet* 39: 1225–1234.
50. Maruyama T, Jiang M, Hsu W (2012) Gpr177, a novel locus for bone-mineral-density and osteoporosis, regulates osteogenesis and chondrogenesis in skeletal development. *J Bone Miner Res* 28: 1150–1159.
51. Gros J, Serralbo O, Marcelle C (2009) WNT11 acts as a directional cue to organize the elongation of early muscle fibres. *Nature* 457: 589–593.
52. Gao B, Song H, Bishop K, Elliot G, Garrett L, et al. (2011) Wnt Signaling Gradients Establish Planar Cell Polarity by Inducing Vangl2 Phosphorylation through Ror2. *Dev Cell* 20: 163–176.
53. Yamaguchi TP, Bradley A, McMahon AP, Jones S (1999) A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. *Development* 126: 1211–1223.
54. Kibar Z, Torban E, McDearmid JR, Reynolds A, Berghout J, et al. (2007) Mutations in VANGL1 associated with neural-tube defects. *N Engl J Med* 356: 1432–1437.
55. Lei YP, Zhang T, Li H, Wu BL, Jin L, et al. (2010) VANGL2 mutations in human cranial neural-tube defects. *N Engl J Med* 362: 2232–2235.
56. Grzeschik K-H, Bornholdt D, Oeffner F, König A, Del Carmen Boente M, et al. (2007) Deficiency of PORCN, a regulator of Wnt signaling, is associated with focal dermal hypoplasia. *Nat Genet* 39: 833–835.
57. Barrott JJ, Cash GM, Smith AP, Barrow JR, Murtaugh LC (2011) Deletion of mouse Porcn blocks Wnt ligand secretion and reveals an ectodermal etiology of human focal dermal hypoplasia/Goltz syndrome. *Proceedings of the National Academy of Sciences* 108: 12752–12757.
58. Petti M, Samanich J, Pan Q, Huang CK, Reinmund J, et al. (2011) Molecular characterization of an interstitial deletion of 1p31.3 in a patient with obesity and psychiatric illness and a review of the literature. *Am J Med Genet A* 155A: 825–832.
59. Kimmel RA, Turnbull DH, Blanquet V, Wurst W, Loomis CA, et al. (2000) Two lineage boundaries coordinate vertebrate apical ectodermal ridge formation. *Genes & Development* 14: 1377–1389.
60. Dassule HR, Lewis P, Bei M, Maas R, McMahon AP (2000) Sonic hedgehog regulates growth and morphogenesis of the tooth. *Development* 127: 4775–4785.
61. Brault V, Moore R, Kutsch S, Ishibashi M, Rowitch DH, et al. (2001) Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. *Development* 128: 1253–1264.
62. Haegel H, Larue L, Ohsugi M, Fedorov L, Herrenknecht K, et al. (1995) Lack of beta-catenin affects mouse development at gastrulation. *Development* 121: 3529–3537.
63. Ishii M, Merrill AE, Chan Y-S, Gitelman I, Rice DPC, et al. (2003) Msx2 and Twist cooperatively control the development of the neural crest-derived skeletogenic mesenchyme of the murine skull vault. *Development* 130: 6131–6142.